Dr. Eric Topol tweeted about a recent article whic
Post# of 154145
(Total Views: 699)
Posted On: 07/14/2023 2:35:16 PM
Dr. Eric Topol tweeted about a recent article which states that "our 1st line of defense vs #SARSCoV2 are interferons, our innate immunity, a complex system not yet exploited for prevention and therapy".
The article is available here:
https://www.cell.com/immunity/fulltext/S1074-7613(23)00275-3
Here is a summary of the article:
Innate immunity and the actions of type I and III interferons (IFNs) are essential for protection from SARS-CoV-2 and COVID-19. Each is induced in response to infection and serves to restrict viral replication and spread while directing the polarization and modulation of the adaptive immune response. Owing to the distribution of their specific receptors, type I and III IFNs, respectively, impart systemic and local actions. Therapeutic IFN has been administered to combat COVID-19 but with differential outcomes when given early or late in infection. In this perspective, we sort out the role of innate immunity and complex actions of IFNs in the context of SARS-CoV-2 infection and COVID-19. We conclude that IFNs are a beneficial component of innate immunity that has mediated natural clearance of infection in over 700 million people. Therapeutic induction of innate immunity and use of IFN should be featured in strategies to treat acute SARS-CoV-2 infection in people at risk for severe COVID-19.
In response to a question from a poster, ohm20 posted an "incomplete list" (his term, not mine!!) of dozens of biomarker/chemokine/inflammatory/immune reactions that are potentially down or up-regulated by Leronlimab.
https://investorshangout.com/post/view?id=6559751
I see IFNs listed two times in ohm's post, but not using the same description the article above uses. ohm20, if you take the time to review the article, please let us know if this reinforces (hopefully) your thoughts about Leronlimab's potential.
Thanks
The article is available here:
https://www.cell.com/immunity/fulltext/S1074-7613(23)00275-3
Here is a summary of the article:
Innate immunity and the actions of type I and III interferons (IFNs) are essential for protection from SARS-CoV-2 and COVID-19. Each is induced in response to infection and serves to restrict viral replication and spread while directing the polarization and modulation of the adaptive immune response. Owing to the distribution of their specific receptors, type I and III IFNs, respectively, impart systemic and local actions. Therapeutic IFN has been administered to combat COVID-19 but with differential outcomes when given early or late in infection. In this perspective, we sort out the role of innate immunity and complex actions of IFNs in the context of SARS-CoV-2 infection and COVID-19. We conclude that IFNs are a beneficial component of innate immunity that has mediated natural clearance of infection in over 700 million people. Therapeutic induction of innate immunity and use of IFN should be featured in strategies to treat acute SARS-CoV-2 infection in people at risk for severe COVID-19.
In response to a question from a poster, ohm20 posted an "incomplete list" (his term, not mine!!) of dozens of biomarker/chemokine/inflammatory/immune reactions that are potentially down or up-regulated by Leronlimab.
https://investorshangout.com/post/view?id=6559751
I see IFNs listed two times in ohm's post, but not using the same description the article above uses. ohm20, if you take the time to review the article, please let us know if this reinforces (hopefully) your thoughts about Leronlimab's potential.
Thanks
(4)
(0)